Brain tumor patients with severe symptoms may get a new treatment option
NCT ID NCT03623347
First seen Jun 18, 2026
Summary
This study tested a combination of two drugs, bevacizumab and temozolomide, given before standard chemoradiotherapy in 70 patients with newly diagnosed glioblastoma who had severe neurological symptoms. The goal was to reduce tumor size and improve symptoms enough to allow patients to receive standard treatment. The study looked at how many patients could then undergo optimal chemoradiotherapy and how their survival and quality of life were affected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU Amiens-Picardie
Amiens, 80054, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab and temozolomide
What this could lead to
If this approach works, it could allow more patients with severe glioblastoma to receive life-extending chemoradiotherapy.
What could go wrong
This is a small, early-phase study with only 70 participants. The drugs may not shrink the tumor enough, and side effects like bleeding or high blood pressure are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.